Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

At OCTSC, an expert discussed the biotech funding environment, market trends and for all key stakeholders in the healthcare space.

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

Pollon Life, a Chinese biotech company backed by Jack Ma’s Yunfeng Capital, has confidentially filed for a Hong Kong IPO that could raise about USD 300 million. The firm, maker of China’s first ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

Currently, the listing process for SGX Mainboard involves reviews by both MAS and SGX RegCo. MAS reviews the issuer’s ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...

The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...

(Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...